The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
|Videos|November 14, 2017
ctDNA Predicts Outcomes in Lung Cancer Patients Receiving Radiation Therapy
This peer-to-peer exchange highlights results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
Advertisement
In this peer-to-peer exchange, Aadel Chaudhuri, MD, PhD, and Maximilian Diehn, MD, PhD, both of the Stanford School of Medicine in California, discuss results of a study that tested whether analyzing circulating tumor DNA (ctDNA) during treatment with chemoradiotherapy could predict outcomes in patients with localized lung cancer.
Chaudhuri presented results of the study at the 2017 American Society for Radiation Oncology Annual Meeting, held earlier this year in San Diego.
Advertisement
Related to this article
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
3
Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT
4
ASH Issues New Myelofibrosis Guidelines With 10 Management Recommendations
5